[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Ibio Inc (IBIO)

Ibio Inc (IBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 62,596
  • Shares Outstanding, K 49,679
  • Annual Sales, $ 100 K
  • Annual Income, $ -33,040 K
  • EBIT $ -24 M
  • EBITDA $ -17 M
  • 60-Month Beta 1.29
  • Price/Sales 630.92
  • Price/Cash Flow N/A
  • Price/Book 0.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.07
  • Number of Estimates 4
  • High Estimate $-0.06
  • Low Estimate $-0.08
  • Prior Year $-0.11
  • Growth Rate Est. (year over year) +36.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2101 +9.08%
on 09/01/26
1.5400 -14.29%
on 08/12/26
-0.0800 (-5.71%)
since 07/31/26
3-Month
1.2101 +9.08%
on 09/01/26
2.1100 -37.44%
on 07/01/26
-0.4400 (-25.00%)
since 06/02/26
52-Week
0.7708 +71.25%
on 09/23/25
3.8200 -65.45%
on 12/10/25
+0.5089 (+62.74%)
since 09/02/25

Most Recent Stories

More News
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary...

IBIO : 1.3200 (+4.76%)
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody...

WFC : 89.29 (+2.59%)
IBIO : 1.3200 (+4.76%)
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody...

IBIO : 1.3200 (+4.76%)
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary...

IBIO : 1.3200 (+4.76%)
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for...

IBIO : 1.3200 (+4.76%)
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases,...

IBIO : 1.3200 (+4.76%)
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove...

IBIO : 1.3200 (+4.76%)
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach ...

IBIO : 1.3200 (+4.76%)
iBio to Participate in Upcoming Healthcare Investor Conferences

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. ( NASDAQ: IBIO ) (“iBio” or the “Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary...

IBIO : 1.3200 (+4.76%)
iBio to Participate in Upcoming Healthcare Investor Conferences

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an AI-driven innovator developing therapies for...

IBIO : 1.3200 (+4.76%)

Business Summary

Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture...

See More

Key Turning Points

3rd Resistance Point 1.3932
2nd Resistance Point 1.3466
1st Resistance Point 1.3033
Last Price 1.3200
1st Support Level 1.2134
2nd Support Level 1.1668
3rd Support Level 1.1235

See More

52-Week High 3.8200
Fibonacci 61.8% 2.6552
Fibonacci 50% 2.2954
Fibonacci 38.2% 1.9356
Last Price 1.3200
52-Week Low 0.7708

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.